Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Pharmaceutical Insights: Ibudilast's R&D Progress and its Mechanism of Action on Drug Target
6 November 2023
This article summarized the latest R&D progress of Ibudilast, the Mechanism of Action for Ibudilast, and the drug target R&D trends for Ibudilast.
Valuable Targets
7 min read
Advances in Clinical Research on Cyclin-dependent Kinase Inhibitor
6 November 2023
CDKs or cyclin-dependent kinase,are a group of enzymes that play a crucial role in regulating the cell cycle in the human body.
Drug Insights
4 min read
Exploring Ipratropium bromide/Albuterol sulfate's Revolutionary R&D Successes
6 November 2023
This article summarized the latest R&D progress of Ipratropium bromide/Albuterol sulfate, the mechanism of action for Ipratropium bromide/Albuterol sulfate, and the drug target R&D trends for Ipratropium bromide/Albuterol sulfate.
Latest Hotspot
3 min read
SparX Biopharma declares FDA approval of IND application for SPX-303, an initial human test of anti-LILRB2/PD-L1 antibody medication
6 November 2023
SparX Biopharmaceutical Corp. happily announces FDA approval of its IND application for SPX-303, a key development in powered antibody therapies and a leading anti-LILRB2/PD-L1 bispecific antibody drug candidate.
Bio Sequence
3 min read
The Competitive Landscape Behind the FDA-approved New Treatment for Biliary Tract Cancer, Keytruda
6 November 2023
According to the Patsnap Bio Sequence Database, the top 10 applicants for the Keytruda patent are Novartis AG with 438 applications, Merck Sharp & Dohme Corp. with 350 applications, and Merck Sharp & Dohme LLC with 299 applications.
Valuable Targets
6 min read
Analysis on the Research Progress of Dihydrofolate Reductase Inhibitor
6 November 2023
DHFR, or dihydrofolate reductase, is an indispensable enzyme required for the survival of most prokaryotic and eukaryotic cells as it is involved in the biosynthesis of essential cellular components.
Drug Insights
4 min read
Decoding Lanadelumab: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
6 November 2023
This article summarized the latest R&D progress of Lanadelumab, the Mechanism of Action for Lanadelumab, and the drug target R&D trends for Lanadelumab.
Latest Hotspot
3 min read
Volastra Therapeutics reports that the initial patient has been treated in the Phase I/II Clinical Study of VLS-1488, a unique KIF18A inhibitor in its innovative compound portfolio
3 November 2023
Volastra Therapeutics has begun dosing the first participant in a Phase I/II clinical trial of VLS-1488, which, along with sovilnesib, forms their portfolio of unique KIF18A inhibitors designed to treat solid tumors with high chromosomal instability.
Drug Insights
4 min read
Deep Scientific Insights on Levomepromazine's R&D Progress, Mechanism of Action, and Drug Target
3 November 2023
This article summarized the latest R&D progress of Levomepromazine, the mechanism of action for Levomepromazine, and the drug target R&D trends for Levomepromazine.
Valuable Targets
6 min read
Analysis on the Clinical Research Progress of FcRn Antagonists
3 November 2023
FcRn, or neonatal Fc receptor, is a crucial protein found in the human body that plays a significant role in the immune system and the pharmacokinetics of therapeutic antibodies.
Drug Insights
5 min read
An In-depth Analysis of Lisocabtagene maraleucel's R&D Progress and Mechanism of Action on Drug Target
3 November 2023
This article summarized the latest R&D progress of Lisocabtagene maraleucel, the Mechanism of Action for Lisocabtagene maraleucel, and the drug target R&D trends for Lisocabtagene maraleucel.
Latest Hotspot
3 min read
Allyx Therapeutics' primary compound, ALX-001, demonstrates safety and toleration through dosage testing and successfully engages with the brains of healthy seniors
3 November 2023
At the 16th Clinical Trials on Alzheimer's Disease convention in Boston on October 27, 2023, clinical-phase biotech firm Allyx Therapeutics revealed findings from their Phase 1a study of ALX-001, their orally administered, pioneering, highly-selective, synapse-focused, disease-modifying neurodegenerative treatment.